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Abstract
Aims/hypothesis The role of non-cardiomyocytes in diabetic cardiomyopathy has not been fully addressed. This study investigated whether endothelial cell calpain plays a role in myocardial endothelial injury and microvascular rarefaction in diabetes,
thereby contributing to diabetic cardiomyopathy.
Methods Endothelial cell-specific Capns1-knockout (KO) mice were generated. Conditions mimicking prediabetes and type 1
and type 2 diabetes were induced in these KO mice and their wild-type littermates. Myocardial function and coronary flow
reserve were assessed by echocardiography. Histological analyses were performed to determine capillary density, cardiomyocyte
size and fibrosis in the heart. Isolated aortas were assayed for neovascularisation. Cultured cardiac microvascular endothelial cells
were stimulated with high palmitate. Angiogenesis and apoptosis were analysed.
Results Endothelial cell-specific deletion of Capns1 disrupted calpain 1 and calpain 2 in endothelial cells, reduced cardiac
fibrosis and hypertrophy, and alleviated myocardial dysfunction in mouse models of diabetes without significantly affecting
systemic metabolic variables. These protective effects of calpain disruption in endothelial cells were associated with an increase
in myocardial capillary density (wild-type vs Capns1-KO 3646.14 ± 423.51 vs 4708.7 ± 417.93 capillary number/high-power
field in prediabetes, 2999.36 ± 854.77 vs 4579.22 ± 672.56 capillary number/high-power field in type 2 diabetes and 2364.87 ±
249.57 vs 3014.63 ± 215.46 capillary number/high-power field in type 1 diabetes) and coronary flow reserve. Ex vivo analysis of
neovascularisation revealed more endothelial cell sprouts from aortic rings of prediabetic and diabetic Capns1-KO mice compared with their wild-type littermates. In cultured cardiac microvascular endothelial cells, inhibition of calpain improved angiogenesis and prevented apoptosis under metabolic stress. Mechanistically, deletion of Capns1 elevated the protein levels of βcatenin in endothelial cells of Capns1-KO mice and constitutive activity of calpain 2 suppressed β-catenin protein expression in
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cultured endothelial cells. Upregulation of β-catenin promoted angiogenesis and inhibited apoptosis whereas knockdown of βcatenin offset the protective effects of calpain inhibition in endothelial cells under metabolic stress.
Conclusions/interpretation These results delineate a primary role of calpain in inducing cardiac endothelial cell injury and
impairing neovascularisation via suppression of β-catenin, thereby promoting diabetic cardiomyopathy, and indicate that calpain
is a promising therapeutic target to prevent diabetic cardiac complications.
Keywords β-Catenin . Calpain . Diabetic cardiomyopathy . Endothelial cells . Neovascularisation

Abbreviations
Ad-CAST Adenoviral vector containing
rat calpastatin
Ad-gal
Adenoviral vector containing
β-galactosidase
CFR
Coronary flow reserve
CMVEC
Cardiac microvascular endothelial cell
E/A ratio
Ratio of maximal early and
late transmitral velocities
GAPDH
Glyceraldehyde-3-phosphate dehydrogenase
HFD
High-fat diet
HIF
Hypoxia-inducible factor
KO
Knockout
LV
Left ventricle
MDA
Malondialdehyde
siRNA
Small interfering RNA
STZ
Streptozotocin
VEGF
Vascular endothelial growth factor

Introduction
By 2030, it is estimated that diabetes will be the seventh leading cause of death [1]. People with diabetes are at increased
risk of developing cardiovascular diseases, which account for
~80% of diabetes-related deaths [2]. Both type 1 and type 2
diabetes can affect cardiac structure and function independent
of vascular defects and hypertension, a condition termed diabetic cardiomyopathy [3]. Diabetic cardiomyopathy is
characterised by early diastolic dysfunction and later systolic
dysfunction and heart failure. The pathogenesis of diabetic
cardiomyopathy remains incompletely understood and effective therapies are limited.
Calpains belong to a family of calcium-dependent cysteine
proteases [4]. Among 15 family members, only calpain 1 and
calpain 2 are expressed in the endothelial cells [5]. Calpain 1
and calpain 2 are heterodimers consisting of a distinct large
80 kDa catalytic subunit called CAPN1 or CAPN2,
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respectively (encoded by the genes CAPN1 and CAPN2), and
a common small 28 kDa regulatory subunit (encoded by
CAPNS1). The small subunit is indispensable for calpain 1
and calpain 2 stability and activity [6]. Both calpain 1 and
calpain 2 activities are negatively regulated by calpastatin
[4]. We have recently reported that cardiomyocyte-specific
deletion of Capns1 reduces adverse cardiac changes in mouse
models of impaired glucose tolerance (induced by feeding a
high-fat diet [HFD]) and type 1 diabetes [7–9]. These findings
indicate a critical role of cardiomyocyte calpain in diabetic
cardiomyopathy.
Whereas dysfunction of cardiomyocytes plays a central
role in diabetic cardiomyopathy, non-cardiomyocytes in the
heart, such as coronary microvascular endothelial cells, are
important in maintaining coronary vessel function, ventricular
homeostasis and cardiac function [10]. Myocardial endothelial cell dysfunction, death and rarefaction contribute to diabetic
cardiac complications [11]. Indeed, diabetes impairs the stability of myocardial microvascular vessels in both diabetic
human myocardial explants and experimental diabetes [12],
and microvascular endothelial dysfunction has been observed
in impaired glucose tolerance, which may explain the increased risk of complications of microvascular origin in impaired glucose tolerance and early type 2 diabetes [13, 14].
However, the causes of coronary microvascular endothelial
cell injury and dysfunction that thereby facilitate diabetic cardiomyopathy remain incompletely understood. Calpain activation has been implicated in endothelial dysfunction and inflammation under diabetic conditions [15–19]. This raises an
intriguing possibility that calpain-mediated endothelial cell
injury and dysfunction may contribute to diabetic
cardiomyopathy.
In this study, we investigated the role of endothelial cell
calpain in diabetic cardiomyopathy using mice with endothelial cell-specific deletion of Capns1.

Methods
Animals The Guide for the care and use of laboratory
animals, 8th edition (2011) (http://grants.nih.gov/grants/
olaw/guide-for-the-care-and-use-of-laboratory-animals.pdf)
was followed. All experimental procedures were approved by
the Animal Use Subcommittee of Soochow University
(Suzhou, China). C57BL/6 mice and mice with endothelial
cell-specific expression of Cre recombinase under the control
of Tie2 (TEK-CRE+/−) were purchased from the Jackson
Laboratory (Sacramento, CA, USA). Mice bearing the
targeted Capns1PZ allele containing loxP sites flanking essential coding exons (Capns1PZ+/+) were generated as previously
described [6]. A breeding programme was implemented at
Soochow University’s animal care facilities.
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Mouse models of diabetes Male mice were allocated to different experimental groups by matching body weight.
Prediabetes was induced by feeding male mice an HFD for
12 weeks starting at age 4 weeks [20]. This HFD contained
26.2% protein, 26.3% carbohydrate and 34.9% fat (% by
weight) (Research Diets, New Brunswick, NJ, USA) [8].
A condition mimicking type 2 diabetes was induced in
male mice (age 4 weeks) by feeding an HFD for 4 weeks,
followed by injection of a single dose of streptozotocin
(STZ, 100 mg/kg, i.p.). HFD was maintained for an additional
8 weeks after STZ injection. At 48 h after STZ injection, mice
were con sidered dia betic only if they e xhibited
hyperglycaemia (≥15 mol/l) [21].
A condition mimicking type 1 diabetes was induced in
adult male mice (2 months old) by consecutive peritoneal
injections of STZ (50 mg kg−1 day−1) for 5 days [7]. At
2 months after induction of diabetes, mice were subjected to
the experiments described below.

Isolation of cardiomyocytes, endothelial cells,
fibroblasts and macrophages
Adult mice ventricular cardiomyocytes were isolated as previously described [22]. Endothelial cells were isolated from
lung tissues using microbeads conjugated with CD31 antibody as previously described [23]. Cardiac fibroblasts were
prepared and cultured as previously described [7]. Peritoneal
macrophages were isolated as previously described [24].
Echocardiography Animals were lightly anaesthetised with
inhalant isoflurane (1–3%) and imaged using a 40 MHz
linear array transducer attached to a preclinical ultrasound
system (Vevo 2100, FUJIFILM VisualSonics, Toronto,
ON, Canada) as previously described [9]. Changes in left
ventricle (LV) end-systolic inner diameter, LV enddiastolic inner diameter, ejection fraction and fractional
shortening were analysed. The pulsed wave Doppler measurements of maximal early and late transmitral velocities
in diastole were obtained in the apical view with a cursor
at mitral valve inflow. The coronary blood flow was measured as previously described [25]. Blinding was carried
out for echocardiographic analysis.
IPGTT An IPGTT was performed as previously described [8].
Determination of capillary density Mice were anaesthetised
with inhalant isoflurane (1–3%). A 50 μl amount of
Griffonia (Bandeiraea) simplicifolia lectin 1 (BS1 lectin,
1 mg/ml, Vector Laboratories, Burlingame, CA, USA) was
directly injected into the LV chamber. After 15 min, the heart
tissues were harvested and fixed in 10% (vol./vol.) formalin
and embedded and sectioned at 5 μm thickness. After
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processing, the sections were incubated with goat anti-BS1
lectin antibody (1:100; Vector Laboratories) and then stained
with Alexa Fluor 594-conjugated rabbit anti-goat IgG (1:500,
Invitrogen, Waltham, MA, USA). The fluorescent signals
were quantified from at least eight random high-power fields
for each section. The results were presented as capillary density per field. Blinding was carried out.
Blood lipid profiles Total cholesterol, triacylglycerol, LDLcholesterol and HDL-cholesterol were measured in blood as
previously described [8].
Mouse aortic ring assay Angiogenic assays of mouse aortic
discs were carried out as previously described [23]. Briefly,
mouse aortas were isolated and 1 mm discs placed in culture
dishes and overlaid with 300 μl Matrigel (Corning, Corning,
NY, USA) and endothelial growth medium. After 5 days of
incubation, vessel outgrowths from aorta explants were
counted.
Histological analyses Total collagen content and cardiomyocyte cross-sectional areas of heart sections were assessed as
previously described [7–9]. Collagen I and collagen III deposition was determined by polarisation microscopy. Blinding
was carried out for these analyses.
Adenoviral infection and DNA transfection of cultured
CMVECs Cardiac microvascular endothelial cells
(CMVECs) (within six passages) (CELLutions
Biosystems, Toronto, ON, Canada) were infected with adenoviral vector containing rat calpastatin ([Ad-CAST]
University of Buffalo, Buffalo, NW, USA) or βgalactosidase ([Ad-gal] Vector Biolabs) at a multiplicity
of infection of 100 plaque-forming units/cell. All experiments were performed after 24 h of adenoviral infection.
CMVECs were transfected with pcDNA3-eGFP/β-catenin
(Addgene), pcDNA3-eGFP, β-catenin CRISPR/Cas9
knockout (KO) plasmid (β-catenin Double Nickase Plasmid)
or a control CRISPR/Cas9 KO plasmid from Santa Cruz
Biotechnology, Dallas, TX, USA, using the jetPRIME DNA
transfection reagent (Polyplus-Transfection, Illkirch, France)
according to the manufacturer’s instructions.
Treatment with siRNA CMVECs were transfected with small
interfering (si)RNAs against mouse Capn1 (siCapn1) or
Capn2 (siCapn2, Santa Cruz Biotechnology), or a scrambled
control siRNA, as previously described [25].
In vitro two-dimensional CMVEC culture In vitro angiogenesis
of CMVECs was assessed using the Endothelial Tube
Formation Assay (Cell Biolabs, San Diego, CA, USA) as
previously described [25]. Tube formation was determined
by measuring the tube length.
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Scratch wound healing assay CMVECs were wounded with a
sterile pipette tip to remove cells by two perpendicular linear
scrapes. After dislodged cells were washed away, the cells
were refed with FBS-free media. Wound closure was
photographed both immediately and 12 h post-wounding at
the same spot. The extent of healing was defined as the difference between the original and remaining wound areas as a
percentage of the original area [26].
Endothelial cell permeability Endothelial cell permeability
was assessed as previously described [27]. Briefly,
CMVECs were infected with Ad-CAST or Ad-gal, and then
were seeded to the insert in upper chamber of transwell (pore
size 0.4 μm). Cells were cultured for 24 h to allow the growth
of a confluent monolayer. After treatment, culture media in the
upper chamber were replaced with 20 μl Evans Blue dye
(0.5%). After 1 h, the liquid was collected from the lower
chamber and spectrophotometric absorbance at 650 nm was
determined.
Determination of oxidative damage Protein carbonyl content
and malondialdehyde (MDA) production in heart tissue lysates were measured using a protein carbonyl content assay
kit (Sigma-Aldrich, St. Louis, MO, USA) and a lipid peroxidation MDA assay kit (Beyotime, Shanghai, China), respectively, according to the manufacturer’s instructions.
Calpain activity Calpain activities were measured in CMVEC
lysates using a fluorescence substrate N-succinyl-LLVYAMC (Cedarlane Laboratories, Burlington, ON, Canada) as
previously described [22].
Analysis of apoptosis Apoptosis was determined by measuring caspase 3 activity and cellular DNA fragmentation as previously described [17].
Real-time RT-PCR Real-time RT-PCR was performed to analyse mRNA expression of collagen I, collagen III, hypoxiainducible factor (HIF)-1α, vascular endothelial growth factor
(VEGF), β-catenin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [7–9].
Western blot analysis The protein levels of CAPN1, CAPN2,
calpastatin, β-catenin, histone H3, c-Myc and GAPDH were
determined by western blot analysis using respective specific
antibodies (1:1000 dilutions, Cell Signaling Technology,
Danvers, MA, USA). The proteins recognised by their antibodies were determined by their molecular mass. Both
CAPN1 and CAPN2 antibodies were validated using wildtype and Capns1 KO cells.
Statistical analysis All data are presented as mean ± SD. Oneor two-way ANOVA followed by Newman–Keuls tests were
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Characterisation of endothelial cell-specific Capns1-KO mice
Mice with endothelial cell-specific Capns1 KO were generated by breeding Capns1PZ+/+ and TEK-CRE+/− mice (electronic supplementary material [ESM] Fig. 1a). As the regulatory
subunit encoded by Capns1 is indispensable for the stability
of calpain 1 and calpain 2 [4], the protein levels of CAPN1
and CAPN2 were decreased by about 90% and 75%, respectively, in microvascular endothelial cells isolated from
Capns1-KO mice compared with wild-type littermates
(Capns1PZ+/+), whereas their levels were not changed in fibroblasts, macrophages and cardiomyocytes from Capns1-KO
mice and their wild-type littermates (ESM Fig. 1b–d),
confirming endothelial cell-specific disruption of calpain in
this Capns1-KO mouse model.
Myocardial function, heart weight, body weight, blood
pressure, blood lipid profiles, blood glucose and glucose tolerance were similar between Capns1-KO mice and their wildtype littermates at age 3 months (Fig. 1, ESM Tables 1–4,
ESM Fig. 2), though the peak glucose levels were higher in
Capns1-KO mice compared with their wild-type littermates
(ESM Fig. 2a). These observations suggest that endothelial
cell-specific disruption of calpain is not deleterious to the heart
and its impact on systemic metabolism is negligible in
Capns1-KO mice.
Deficiency of endothelial cell Capns1 protects myocardial
function in diabetic mice Both Capns1-KO mice and their
wild-type littermates exhibited similar prediabetic changes [20], including obesity, hyperlipidaemia and impaired
glucose tolerance (ESM Tables 1 and 3, ESM Fig. 2b).
Echocardiographic analysis revealed a reduction in fractional shortening and the ratio of maximal early and late
transmitral velocities (E/A ratio) in prediabetic wild-type
mice, indicative of myocardial dysfunction. However,
deletion of Capns1 attenuated myocardial dysfunction
in prediabetic Capns1-KO mice (Fig. 1a, b and ESM
Table 4) while not changing systemic metabolic variables or blood pressure (ESM Tables 1–3, ESM Fig. 2).
Myocardial function was decreased in wild-type type
1 and type 2 diabetic mice (Fig. 1a, b), but was relatively maintained in Capns1-KO diabetic mice without
changes in systemic metabolic variables (ESM Tables 1
and 3, ESM Fig. 2). These results suggest endothelial
cell calpain has a role in myocardial dysfunction in
diabetic mice.
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Fig. 1 Assessment of myocardial function. Prediabetes, type 2 diabetes
and type 1 diabetes were induced in Capns1-KO mice and their wild-type
littermates. Myocardial function was assessed by echocardiographic analysis. (a) LV fractional shortening. (b) E/A ratio. Data are mean ± SD, n =
5–8 mice in each group. *p < 0.05 vs wild-type, non-diabetic mice and
†
p < 0.05 vs wild-type mice in the same category (two-way ANOVA
followed by Newman–Keuls test). LVFS, LV fractional shortening; ND,
non-diabetic; preD, prediabetes; T1D, type 1 diabetes; T2D, type 2 diabetes; WT, wild-type

Deletion of endothelial cell Capns1 reduces myocardial hypertrophy and fibrosis in diabetic mice Collagen deposition
and cardiomyocyte cross-sectional area (i.e. cell size) were
significantly increased in hearts of prediabetic and diabetic
mice compared with non-diabetic mouse hearts, indicative of
cardiomyocyte hypertrophy and fibrosis (Fig. 2a–c), two characteristic changes in diabetic cardiomyopathy [3]. However,
deletion of Capns1 significantly reduced myocardial hypertrophy and fibrosis in prediabetes and diabetes. As additional
evidence, deletion of Capns1 attenuated the deposition and
mRNA levels of collagen I and collagen III in prediabetic
mouse hearts (ESM Fig. 3a–e).
Coronary vascular dysfunction and microvascular rarefaction
in diabetic mouse hearts are attenuated by endothelial cellspecific Capns1-KO To determine coronary vascular function,
we analysed coronary flow reserve (CFR) [28]. CFR was significantly decreased in mice with prediabetes and diabetes.
This decrease was significantly less in Capns1-KO mice
(Fig. 3a), implicating endothelial cell calpain in diabetic coronary vascular dysfunction.
As coronary microvascular rarefaction occurs in diabetic
hearts [29, 30], and can impair CFR [12], we examined capillary density in diabetic mouse hearts. Both prediabetes and
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Fig. 2 Determination of fibrosis
and cardiac hypertrophy. (a)
Representative Picrosirius Red
staining for collagen deposition
(red colour) from Capns1-KO
mice and their wild-type
littermates under non-diabetic or
diabetic conditions (scale bar,
100 μm). (b) Quantitative data for
total collagen deposition in hearts.
(c) Cross-sectional
cardiomyocyte area. Data are
mean ± SD, n = 4–6 hearts in each
group. *p < 0.05 vs wild-type,
non-diabetic mice and †p < 0.05
vs wild-type mice in the same
category (two-way ANOVA
followed by Newman–Keuls
test). ND, non-diabetic; preD,
prediabetes; T1D, type 1 diabetes;
T2D, type 2 diabetes; WT, wildtype
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diabetes decreased capillary density in wild-type mouse hearts
(Fig. 3b, c); however, this phenotype was suppressed in
Capns1-KO mice (wild-type vs Capns1-KO 3646.14 ±
423.51 vs 4708.7 ± 417.93 capillary number/high-power field
in prediabetes, 2999.36 ± 854.77 vs 4579.22 ± 672.56 capillary number/high-power field in type 2 diabetes and 2364.87
± 249.57 vs 3014.63 ± 215.46 capillary number/high-power
field in type 1 diabetes). The reduction of coronary capillary
density was associated with increases in protein carbonyl content and MDA production and the expression of HIF-1α and
VEGF in prediabetic hearts, suggesting a hypoxic response;
these effects were prevented by deletion of Capns1 (ESM Fig.
4a–d).
As impaired neovascularisation contributes to coronary microvascular rarefaction in diabetes [31, 32], we analysed neovascularisation in isolated aortic rings. Capillary-like outgrowth of endothelial sprouts was significantly impaired in
aortic rings from wild-type prediabetic and type 2 diabetic
mice (Fig. 3d, e), but it was relatively maintained in
Capns1-KO mice with prediabetes and type 2 diabetes. A
similar observation was made with aortic rings from nondiabetic mice on culturing with, to provide metabolic stress,
high palmitate (100 μmol/l), high palmitate (50 μmol/l) plus
high glucose (15 mmol/l) or high glucose (30 mmol/l) (ESM
Fig. 5a, b). In the absence of endothelial Capns1, the extent of
aortic sprouting was significantly greater when compared with
tissues taken from wild-type littermates under the same metabolic stress, though considerably lower than in the control

T2D

T1D

ND

preD

T2D

T1D

environment (incubation with oleate). These results indicate
that deletion of endothelial cell Capns1 benefits aortic neovascularisation in diabetes.
Inhibition of calpain improves angiogenesis and prevents apoptosis in CMVECs under metabolic stress To provide direct
evidence to support the role of calpain in endothelial injury
and angiogenesis, we infected CMVECs with Ad-CAST or
Ad-gal, and then incubated them with high palmitate (to mimic metabolic stress) or oleate (100 μmol/l). High palmitate
increased calpain activity (ESM Fig. 6), impaired tube formation (Fig. 4a, c), suppressed wound healing (Fig. 4b, d) and
increased apoptosis in CMVECs (Fig. 4e, f). All these effects
of palmitate were prevented by infection with Ad-CAST (Fig.
4a–f). A similar protective effect of calpain inhibition with
Ad-CAST was made when CMVECs were incubated with
high NEFA (50 μmol/l palmitate +50 μmol/l oleate) in combination with high glucose (15 mmol/l) (ESM Fig. 7).
Consistently, incubation with calpain inhibitor III achieved
similar protective effects in CMVECs under metabolic stress
(ESM Fig. 8). Although high palmitate increased the permeability of endothelial cells, inhibition of calpain did not affect
the permeability (ESM Fig. 9). These results demonstrate that
inhibition of calpain promotes angiogenesis and protects endothelial cells under metabolic stress.
Constitutive activities of calpain suppress β-catenin protein
expression in endothelial cells To investigate the mechanisms
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n = 3 different mice in each group (at least six aortic rings analysed for
each mouse). *p < 0.05 vs wild-type, non-diabetic mice and †p < 0.05 vs
wild-type mice in the same category (two-way ANOVA followed by
Newman–Keuls test). H/B; hyperaemic/baseline; HPF, high-power field;
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by which calpain impairs neovascularisation and induces endothelial injury, we focused on β-catenin as it has been
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Fig. 4 Effects of calpastatin upregulation on angiogenesis and apoptosis.
Cultured CMVECs were infected with Ad-CAST or Ad-gal as a control in
the presence of high palmitate or oleate. (a) A representative micrograph
of endothelial cell tube formation (scale bar, 100 μm). (b) A representative micrograph of endothelial cell wound healing (scale bar, 200 μm). (c,
d) Quantitative data for endothelial cell tube formation, determined by
tube length (c), and percentage healing (d). (e) Caspase 3 activity. (f)
DNA fragmentation. Data are mean ± SD, n = 5 independent cell batches.
*p < 0.05 vs oleate + Ad-gal and †p < 0.05 vs palmitate + Ad-gal (twoway ANOVA followed by Newman–Keuls test)

implicated in angiogenesis and calpain induces its proteolysis
[33, 34]. The protein levels of β-catenin were much higher in
endothelial cells of Capns1-KO mice compared with their
wild-type littermates (Fig. 5a), whereas the protein levels of
β-catenin in whole-heart lysates did not differ between
Capns1-KO and wild-type mice (Fig. 5b), suggesting that βcatenin protein may not increase in cardiomyocytes. To provide direct evidence, we showed that infection with Ad-CAST
upregulated β-catenin protein in CMVECs (Fig. 5c, d), but it
did not increase the mRNA levels of β-catenin (Fig. 5e).
Although high palmitate (ESM Fig. 10a, b) and prediabetes
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Fig. 5 Measurement of calpain and β-catenin expression. (a)
Microvascular endothelial cells were isolated from Capns1-KO mice
and their wild-type littermates. A representative western blot for β-catenin and GAPDH from two of four different hearts in each group, together
with quantification of β-catenin protein levels relative to GAPDH, showing that the protein levels of β-catenin are much higher in endothelial
cells from KO compared with wild-type mice. (b) β-Catenin and
GAPDH protein in whole-heart lysates. A representative western blot
for β-catenin and GAPDH from two of four different hearts in each
group, together with quantification of β-catenin protein levels relative
to GAPDH. (c–e) Cultured CMVECs were infected with Ad-CAST or
Ad-gal as a control. At 6, 12 and 24 h after infection, the protein levels of
calpastatin, β-catenin and GAPDH were determined by western blot
analysis. The mRNA levels of β-catenin and Gapdh were analysed by

real-time RT-PCR. (c) Representative western blots for calpastatin, βcatenin and GAPDH protein. (d) β-catenin protein levels relative to
GAPDH. (e) mRNA level of β-catenin relative to Gapdh. (f–h)
Cultured CMVECs were transfected with siRNAs for Capn1 (siCapn1)
and Capn2 (siCapn2) or scramble siRNA as a control. (f) Representative
western blots for CAPN1, β-catenin and GAPDH. (g) Representative
western blots for CAPN2, β-catenin and GAPDH. (h) β-Catenin protein
levels relative to GAPDH. The same scramble siRNA was used in two
experiments. Data are mean ± SD, n = 5 independent cell batches.
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[a] and [h]). CAST, calpastatin; ND, non-diabetic; preD, prediabetes;
T1D, type 1 diabetes; T2D, type 2 diabetes; WT, wild-type

(Fig. 5b) did not change the total protein levels of β-catenin,
high palmitate significantly reduced the nuclear protein levels
of β-catenin in endothelial cells (ESM Fig. 10c, d), indicative
of its inactivation, which was prevented by calpain inhibition.
In contrast, inhibition of calpain induced c-Myc protein expression in both oleate- and palmitate-stimulated endothelial

cells (ESM Fig. 10e, f), suggesting that nuclear accumulation
of β-catenin may not account for c-Myc induction in this
scenario. Furthermore, knockdown of CAPN2 but not
CAPN1 increased β-catenin protein (Fig. 5f–h). These results
suggest that the constitutive activity of calpain 2 suppresses βcatenin protein expression in endothelial cells.
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Upregulation of β-catenin promotes angiogenesis in CMVECS
under metabolic stress To investigate the role of β-catenin in
angiogenesis and apoptosis, we introduced pcDNA3-eGFP/
β-catenin into CMVECs to upregulate β-catenin protein. An
empty plasmid pcDNA3-eGFP served as a control. After 24 h,
we incubated these cells with palmitate or oleate (100 μmol/l).
Palmitate decreased tube formation, suppressed wound
healing and induced apoptosis in CMVECs (Fig. 6a–f).
These effects of palmitate were not seen in cells with upregulated β-catenin (Fig. 6a–f, ESM Fig. 11a).
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Knockout of β-catenin offsets the pro-angiogenic and antiapoptotic effects of calpain inhibition in CMVECS under metabolic stress To determine whether inhibition of calpain promotes angiogenesis and inhibits apoptosis through β-catenin
signalling, we knocked out β-catenin in CMVECs using
CRISPR/cas9 (ESM Fig. 11b) and then infected these cells
with Ad-CAST or Ad-gal. At 24 h after infection, we exposed
these cells to palmitate or oleate (100 μmol/l). Palmitate decreased tube formation, suppressed wound healing and induced apoptosis in CMVECs (Fig. 7a–d). These effects of
palmitate were reduced by infection with Ad-CAST.
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or oleate. (a) A representative micrograph of endothelial cell tube formation (scale bar, 100 μm). (b) A representative micrograph of wound
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tube formation, determined by tube length (c), and percentage healing (d).
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However, knockdown of β-catenin offset the protective effects conferred by infection with Ad-CAST in palmitatestimulated CMVECs (Fig. 7a–d).

Discussion
The major finding of this study is that endothelial cell-specific
disruption of calpain reduced diabetic cardiomyopathy in
mice (Figs 1 and 2). The protective effect of endothelial cellspecific calpain disruption may be attributed to attenuated
endothelial injury and improved angiogenesis in diabetic
hearts and CMVECs under metabolic stress (Figs 3 and 4).
Furthermore, the constitutive activity of calpain 2 suppressed
β-catenin protein expression in endothelial cells (Fig. 5), and
upregulation of β-catenin promoted angiogenesis and
inhibited apoptosis; knockout of β-catenin offset the effects
of calpain inhibition on angiogenesis and apoptosis in endothelial cells under metabolic stress (Figs 6 and 7). These findings highlight a critical role of endothelial cell calpain in coronary vascular injury and microvascular rarefaction, contributing to diabetic cardiomyopathy.
Calpain has been implicated in diabetic cardiomyopathy.
Calpain is activated in the diabetic heart and in cultured
cardiomyocytes under metabolic stress [7–9]. In
cardiomyocytes, inhibition of calpain prevented apoptosis induced by high glucose and palmitate [7, 8]. In mouse models
of prediabetes and type 1 diabetes, we recently demonstrated
that cardiomyocyte-specific deletion of Capns1 reduced diabetic cardiomyopathy [7–9]. These earlier studies indicated a
critical role of cardiomyocyte calpain in diabetic cardiomyopathy. The present study provides direct evidence for a primary
role of endothelial cell calpain in diabetic cardiomyopathy
(Figs 1 and 2). The role of endothelial cell calpain may be
associated with coronary circulation dysfunction in the diabetic heart as deletion of Capns1 increased CFR [35] (Fig. 3a).
Thus, our observations are consistent with a model whereby
calpain activation compromises coronary circulation, which
can directly impair myocardial function in diabetes.
Compromised coronary circulation may induce a condition
of sub-ischaemia in hearts, as supported by increases in oxidative damage, HIF-1α and VEGF expression (ESM Fig. 4),
which initiates cardiomyocyte death and subsequent myocardial remodelling [36, 37], characteristic changes in diabetic
cardiomyopathy [3]. This may partially explain how calpainmediated endothelial cell injury and dysfunction contributes
to myocardial hypertrophy and fibrosis in diabetic cardiomyopathy. However, other mechanisms merit future investigation. Although deleting endothelial cell calpain may have unknown systemic impacts that potentially confound the interpretation of our findings, our studies using cultured endothelial cells and aortic rings provide direct evidence supporting
the role of calpain in endothelial injury and angiogenesis (Figs
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3 and 4). Furthermore, deficiency of endothelial cell Capns1
did not affect systemic metabolic variables and blood pressure. Thus, the global effects of Capns1 deletion, if any, may
be negligible in this scenario.
Certain pathophysiological conditions can influence CFR.
Among them, coronary vascular dysfunction (e.g. mild to
moderate coronary artery stenosis, myocardial vascular dysfunction and capillary rarefaction) is directly related to abnormalities of endothelial cells [38]. As myocardial capillary rarefaction and vascular dysfunction are observed in cases where
no coronary artery stenosis has been reported in diabetes [12],
reduced CFR is likely caused by capillary rarefaction and
vascular dysfunction [35]. Indeed, capillary density was significantly decreased in diabetic mouse hearts (Fig. 3b, c); this
phenotype was suppressed by endothelial cell-specific disruption of calpain. The detrimental role of calpain in endothelial/
vascular dysfunction has also been demonstrated in diabetes.
In cultured endothelial cells, calpain activation decreased NO
production and promoted apoptosis under metabolic stress
[18]. This was further confirmed in vasculature from mouse
and rat models of type 1 and type 2 diabetes [15, 39]. Calpain
was also reported to cleave prostacyclin synthase in mesenteric artery from type 1 diabetic mice; the consequent reduction
of prostacyclin led to endothelial dysfunction [19]. In addition, previous studies have reported that calpain inhibition
maintains the microcirculatory endothelial cell barrier in type
1 and type 2 diabetes [15–17], which is not supported by our
study on endothelial cell permeability induced by palmitate
(ESM Fig. 9). The cause of this discrepancy is unknown.
Although the exact mechanisms by which calpain disruption in endothelial cells improves capillary density in
diabetic hearts are currently unknown, our data suggest
that decreased endothelial injury and improved neovascularisation may be important in this scenario (Figs 3d, e and
4). Previous studies have also demonstrated that inhibition
of calpain promotes angiogenesis in a variety of experimental models. In an in vitro study on pericyte regulation
of nascent endothelial tubes, calpain activation mediated
chemokine (C-X-C motif) receptor 3 (CXCR3)-induced
repression of angiogenic vessel formation in human dermal
microvascular endothelial cells [40]. More recently, it was
reported that calpain 1 activation decreased circulating angiogenic cells in response to IFN-β, and thus inhibited
vessel formation [41], and that thromboxane-induced
calpain 2 activation inhibited endothelial cell differentiation of autologous adipose-derived stromal cells and angiogenesis in ischaemic mouse hindlimbs [34]. However,
these reports, together with our present findings, contrast
with some prior studies in non-cardiac endothelial cells
induced by VEGF, IL-6 or shear stress, and in skin wound
healing during diabetes [42–44]. These differences suggest
that calpain may modulate angiogenesis via multiple
mechanisms, depending on conditions and organs/tissues.
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The present study demonstrates that inhibition of calpain
promotes angiogenesis and prevents apoptosis through upregulation of β-catenin under metabolic stress (Figs 6 and 7).
Silencing of Capn2 elevated β-catenin levels, whereas silencing of Capn1 did not alter the protein levels of β-catenin under
normal conditions (Fig. 5g, h). Relevantly, deficiency of
Capns1 increased β-catenin protein levels in endothelial cells
of Capns1-KO mice (Fig. 5a). These data suggest that constitutive activity of calpain 2 suppresses β-catenin protein expression, which is consistent with a study in human osteosarcoma cells [33]. Several studies have also shown that calpain
cleaves β-catenin protein [45, 46]. In line with these reports,
our data show that inhibition of calpain increased the protein
levels of β-catenin without changing its mRNA levels (Fig.
5a–e). Metabolic stress did not increase β-catenin expression
in endothelial cells and heart tissues. However, calpain inhibits β-catenin activation under metabolic stress.
Studies have implicated β-catenin in diabetic cardiomyopathy. In the hearts from STZ-induced diabetic rats, β-catenin
expression was increased [47], suggesting that β-catenin may
play a role in diabetic cardiomyopathy. Indeed, glucagon-like
peptide-mediated activation of β-catenin prevented apoptosis
in palmitate-stimulated cardiomyocytes [48]. Although the
present study shows increased β-catenin protein in endothelial
cells from HFD-fed mice, its levels in whole-heart tissues do
not differ between HFD-fed mice and those fed a normal diet.
This discrepancy between rats with STZ-induced diabetes and
HFD-fed mice suggests different responses to type 1 diabetes
and HFD in terms of β-catenin induction. Deletion of Capns1
in endothelial cells provides similar cardiac protection in different diabetic models. This suggests that calpain activation
may be a common mechanism contributing to adverse cardiac
changes in different types of diabetes. Indeed, we show that
inhibition of calpain prevents apoptosis and improves angiogenesis in endothelial cells under different metabolic stresses,
including high glucose and high palmitate alone or in combination, and in diabetic hearts (Figs 3d, e and 4 and ESM Figs
5, 7 and 8). Furthermore, disruption of calpain in
cardiomyocytes reduces adverse cardiac changes similarly in
different type 1 diabetic and HFD-fed mice [7–9].
In summary, we have demonstrated a primary role for
calpain-mediated coronary microvascular endothelial cell
injury and dysfunction in the pathogenesis of diabetic
cardiac complications. This effect of endothelial cell
calpain may be mediated through impaired neovascularisation and endothelial injury in diabetic cardiomyopathy. Given that cardiomyocyte calpain also plays an important role in diabetic cardiomyopathy [6, 8] and that
calpain activation induces beta cell death [49], peripheral vascular dysfunction [15–17] and retinopathy [50]
during diabetes, pharmaceutical approaches targeting
calpain may be a useful therapy for diabetes and its
cardiovascular complications.
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